Assessment of Geriatric Evaluations Impact on New AML Guidance
About this study
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.
- Condition
- AML, Adult
- Sponsor
- Abramson Cancer Center at Penn Medicine
Who can join
- Age
- 50 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 50 years
- Study condition: AML, Adult
- AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy
- New diagnosis being considered for new line of treatment
- Age ≥ 50 years.
- Performance status 0,1, and 2
Exclusion 2
- Inability to understand or unable to sign a written informed consent
- Unable to fill out questionnaires on their own and/or do not have someone to help complete them
Where
1 site, 1 recruiting
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States
Contact
-
Colleen Redlinger
2152209693 colleen.redlinger@pennmedicine.upenn.edu
-
Catherine Lai, MD
2153600561 Catherine.Lai@Pennmedicine.upenn.edu
Potential match only. Final eligibility is determined by the study team.